What makes amycretin, now called zenagamtide, different from tirzepatide?

Zenagamtide is the name now used for amycretin. It combines GLP-1 and amylin activity in one molecule, and the publications also describe calcitonin receptor agonism. Tirzepatide instead combines GIP and GLP-1 receptor activity. Those targets explain why the compounds are scientifically distinct, but they do not predict which is best for an individual. Zenagamtide’s oral and injectable formulations have separate clinical reports and should not be combined into a single headline result.[1][2][3][4]

The oral phase 2 study in type 2 diabetes demonstrated improved HbA1c compared with placebo; the injectable program also reported weight reductions. A glucose-control endpoint is not a direct test of fat loss or muscle preservation. Gastrointestinal adverse events and treatment discontinuations matter alongside efficacy. Comparisons with tirzepatide require attention to diabetes status, treatment duration, formulation and statistical handling of discontinued treatment. Different trials do not establish that zenagamtide is superior, and an injectable result does not establish the same effect from an oral product.[1][2][3][4]